- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06154512
Une étude observationnelle prospective multicentrique dans le monde réel sur l'HPN en Chine (ReWoPNH)
Une étude observationnelle prospective multicentrique dans le monde réel sur l'hémoglobinurie paroxystique nocturne (HPN) en Chine
As a rare disease listed in the First Catalogue of Rare Diseases in China (National Health Commission of the People's Republic of China, 2019), PNH is poorly studied in China subse-quently leading to the inadequate elucidation of disease characteristics and clinical outcomes. Eculizumab was recently approved by NMPA. The availability of Eculizumab in China pro-vides people living with PNH with a new treatment option that can reduce disease symptoms and prevent the dysregulated complement system from causing further damage. A Phase Ⅳ study is necessary to understand the natural history of disease and the clinical outcomes with different medical interventions.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra-rare and life-threatening acquired disorder of the pluripotent hematopoietic stem cell and therefore can affect erythrocytes, leukocytes, thrombocytes and probably some endothelial cells. These hematopoietic stem cells have acquired a somatic mutation in the phosphatidylinositol glycan class A (PIG-A) This gene is required for the synthesis of the glycosyl phosphatidyl-inositol (GPI) anchor, which is necessary to attach some proteins to the blood cell membrane. Therefore, a lack of two important complement regulatory proteins is observed on the cell surface: 'decay-accelerating factor' (DAF), also called 'CD55' and 'membrane inhibitor of reactive lysis' (MIRL), also called 'CD59' Thus, red blood cells are more vulnerable to the attack by the complement activation product MAC (complement membrane attack complex). This leads to a complement-mediated intravascular hemolysis. The predisposition of venous thrombosis, hemolytic anemia, complete thrombocytopenia, and thrombosis are the three main characteristics of the disease. Its incidence is not really known but estimated at 0.1~0.6/100 000 per-sons/yr, and prevalence is estimated at 1~4 cases/100,000 persons/yr. PNH was listed in the First Catalogue of Rare Diseases in China, and its incidence was previously reported to be 1/100,000 persons/year, peak onset age 20~40 years.
PNH can be classified into 3 different forms: classical PNH, PNH associated with aplastic anemia (PNH-AA), and subclinical PNH, based on clinical features, bone marrow characteristics, and the size of the mutant clone. The traditional treatment of PNH is still aimed at "protecting" the PNH clone, reducing complement attack and destruction, and alleviating hemolysis with symptomatic supportive therapy. In acute hemolytic episodes, could be administered adrenal glucocorticoids, complemented by cell membrane stabilizers, folic acid, and alkaline drugs. In case of PNH-AA syndrome, treatment with androgens and immunosuppressants may be used; anticoagulation and heparin therapy should be given for the occurrence of thrombosis; other symptomatic supportive treatments include transfusion of red blood cells and platelets if necessary as well as antibacterial drugs in case of infection. Bone marrow transplantation is the only curative therapy for PNH presupposes, but patient need to achieve complete remission with chemotherapy first and a suitable donor is needed.
Besides supportive care, global guidance/consensus also recommend C5 complement inhibitor Eculizumab as a treatment method, and its use could significantly improve 5-year survival rate to 95.5%. Eculizumabis a humanized, first-in-class, anti-C5 antibody that binds with high affinity to C5 and blocks the terminal complement-C5a and C5b-9 formation, reducing the chronic uncontrolled complement activation and its consequences. Eculizumab has been approved for PNH by National Medical Products Administration in August, 2022.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
-
Hangzhou, Chine
- Research Site
-
-
Anhui
-
Hefei, Anhui, Chine, 230002
- Research Site
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Chine, 100000
- Research Site
-
Beijing, Beijing Municipality, Chine, 100044
- Research Site
-
-
Guangdong
-
Guangzhou, Guangdong, Chine, 510080
- Research Site
-
Guangzhou, Guangdong, Chine, 510180
- Research Site
-
Guangzhou, Guangdong, Chine, 510515
- Research Site
-
-
Guangxi
-
Nanning, Guangxi, Chine, 530021
- Research Site
-
-
Guizhou
-
Guiyang, Guizhou, Chine, 550004
- Research Site
-
-
Hebei
-
Shijiazhuang, Hebei, Chine, 050000
- Research Site
-
-
Heilongjiang
-
Harbin, Heilongjiang, Chine, 150001
- Research Site
-
-
Henan
-
Zhengzhou, Henan, Chine, 450003
- Research Site
-
Zhengzhou, Henan, Chine, 450052
- Research Site
-
Zhengzhou, Henan, Chine, 463599
- Research Site
-
-
Hubei
-
Wuhan, Hubei, Chine, 430030
- Research Site
-
Wuhan, Hubei, Chine, 430000
- Research Site
-
-
Hunan
-
Changsha, Hunan, Chine, 410008
- Research Site
-
Changsha, Hunan, Chine, 410005
- Research Site
-
-
Jiangsu
-
Nanjing, Jiangsu, Chine, 210029
- Research Site
-
Nantong, Jiangsu, Chine, 226001
- Research Site
-
Xuzhou, Jiangsu, Chine, 221002
- Research Site
-
-
Jiangxi
-
Nanchang, Jiangxi, Chine, 330006
- Research Site
-
Nanchang, Jiangxi, Chine, 330008
- Research Site
-
-
Jilin
-
Changchun, Jilin, Chine, 130021
- Research Site
-
-
Liaoning
-
Shenyang, Liaoning, Chine, 110001
- Research Site
-
-
Shandong
-
Jinan, Shandong, Chine, 250000
- Research Site
-
Qingdao, Shandong, Chine, 266000
- Research Site
-
Zibo, Shandong, Chine, 255090
- Research Site
-
-
Shangdong
-
Linyi, Shangdong, Chine, 276034
- Research Site
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Chine, 200040
- Research Site
-
Shanghai, Shanghai Municipality, Chine, 200336
- Research Site
-
-
Shanxi
-
Taiyuan, Shanxi, Chine, 030000
- Research Site
-
Xi’an, Shanxi, Chine, 710061
- Research Site
-
Xi’an, Shanxi, Chine, 710068
- Research Site
-
-
Sichuan
-
Chengdu, Sichuan, Chine, 610041
- Research Site
-
Chengdu, Sichuan, Chine, 610072
- Research Site
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Chine, 300020
- Research Site
-
Tianjin, Tianjin Municipality, Chine, 300052
- Research Site
-
Tianjin, Tianjin Municipality, Chine, 300190
- Research Site
-
-
Yunnan
-
Kunming, Yunnan, Chine, 650034
- Research Site
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Study Population:
Number of patients (estimate): 1000; Inclusion Criteria
- Patients of any age;
- Diagnosed PNH with detected proportion of PNH clone cells of at least 1%;
- Patient or patient's family must be willing and able to give written informed consent.
Exclusion Criteria
- Current or previous treatment with a non-eculizumab complement inhibitor;
- Patients in other PNH clinical trials.
- Unable to give written informed consent.
La description
Inclusion Criteria
- Patients of any age;
- Diagnosed PNH with detected proportion of PNH clone cells of at least 1%;
- Patient or patient's family must be willing and able to give written informed consent.
Exclusion Criteria
- Current or previous treatment with a non-eculizumab complement inhibitor;
- Patients in other PNH clinical trials.
- Unable to give written informed consent.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Hemolysis:Concentration of LDH changes at each visit from base-line, of all patients
Délai: 12 months
|
To characterize the progression of PNH |
12 months
|
|
Number and percentage of patients with thrombosis within follow-up
Délai: 12 months
|
To characterize the progression of PNH |
12 months
|
|
average number of units of packed RBCs transfused per month, of all patients
Délai: 12 months
|
To characterize the progression of PNH |
12 months
|
|
Number and percentage of patients with renal failure within follow-up
Délai: 12 months
|
To characterize the progression of PNH |
12 months
|
|
Number and percentage of patients with pulmonary hypertension within follow-up
Délai: 12 months
|
To characterize the progression of PNH |
12 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number and percentage of patients with each symptom of interest within follow-up
Délai: 12 months
|
To describe clinical characteristics of patients with PNH in China |
12 months
|
|
Demographics at baseline of all patients
Délai: baseline
|
To describe clinical characteristics of patients with PNH in China |
baseline
|
|
Number and percentage of patients receiving each type of treatment method at baseline and each visit within follow up, including glucocorticoid, red blood cell transfusion, other supportive treatment, bone marrow transplant, eculizumab, of all patients
Délai: 12 months
|
To describe the treatment pattern of PNH in China |
12 months
|
|
All serious adverse events (SAEs)of PNH among eculizumab-treated patients
Délai: 12 months
|
To describe the safety of Eculizumab treatment via Serious Adverse Events |
12 months
|
|
Standard descriptive statistics of pregnancy status
Délai: 12 months
|
To describe clinical characteristics of patients with PNH in China |
12 months
|
|
Standard descriptive statistics of lactation status
Délai: 12 months
|
To describe clinical characteristics of patients with PNH in China |
12 months
|
|
Standard descriptive statistics of PNH classification
Délai: 12 months
|
To describe clinical characteristics of patients with PNH in China |
12 months
|
|
Standard descriptive statistics of flow cytometry results
Délai: 12 months
|
To describe clinical characteristics of patients with PNH in China |
12 months
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Concentration of LDH changes at each visit from base-line of PNH among eculizumab-treated patients
Délai: 12 months
|
Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients |
12 months
|
|
Number and percentage of patients with thrombosis within follow up among eculizumab-treated patients
Délai: 12 months
|
Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients |
12 months
|
|
average number of units of packed RBCs transfused per month within 12 months v
Délai: 12 months
|
Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients |
12 months
|
|
Number and percentage of patients with renal failure within follow up among eculizumab-treated patients
Délai: 12 months
|
Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients |
12 months
|
|
Number and percentage of patients with pulmonary hypertension (PH) within follow up among eculizumab-treated patients
Délai: 12 months
|
Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients |
12 months
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- D7414R00001
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Délai de partage IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Critères d'accès au partage IPD
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .